Sandeep Laumas - 10 Sep 2025 Form 4 Insider Report for Instil Bio, Inc. (TIL)

Reporting relationship: CFO and CBO
Issuer ticker: TIL
Reported as of: 10 Sep 2025
Net transaction value: -$339,627
SEC form: 4
Accepted by SEC: 12 Sep 2025, 17:00:55 UTC
Prior SEC filing: 30 Jul 2025
Next SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandeep Laumas, M.D.

Key filing fact

Sandeep Laumas filed Form 4 for Instil Bio, Inc. (TIL) on 12 Sep 2025.

Key facts

This page summarizes Sandeep Laumas's Form 4 filing for Instil Bio, Inc. (TIL).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Sep 2025, 17:00.

Change

Previous filing in this sequence was filed on 30 Jul 2025.
Current net transaction value: -$339,627.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721664 Primary reporting owner

Laumas Sandeep

Relationship: CFO and CBO
Address: C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS
Signature: /s/ Sandeep Laumas, M.D.
Signature date: 12 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TIL transaction

Common Stock

Options Exercise

Transaction value: $197,200
Shares: +17,000
Change %
Price: $11.60
Shares after: 17,000
Date: 10 Sep 2025
Ownership: Direct

TIL transaction

Common Stock

Options Exercise

Transaction value: $164,840
Shares: +13,000
Change %: +76%
Price: $12.68
Shares after: 30,000
Date: 10 Sep 2025
Ownership: Direct

TIL transaction

Common Stock

Sale

Transaction value: $404,099
Shares: -17,539
Change %: -58%
Price: $23.04
Shares after: 12,461
Date: 10 Sep 2025
Ownership: Direct
Footnotes: F1

TIL transaction

Common Stock

Sale

Transaction value: $297,569
Shares: -12,461
Change %: -100%
Price: $23.88
Shares after: 0
Date: 10 Sep 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TIL transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -17,000
Change %: -50%
Price: $0.000000
Shares after: 17,000
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $11.60
Footnotes: F3

TIL transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -13,000
Change %: -30%
Price: $0.000000
Shares after: 30,000
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $12.68
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

Footnote F2

The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

Footnote F3

Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter.

Footnote F4

Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter.